Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 18 clinical trials
featured
A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy

This study will look to see if ofatumumab works and is safe in adults with relapsing multiple sclerosis (MS) who are switching from their current oral medicines (dimethyl fumarate or fingolimod

multiple sclerosis
relapsing multiple sclerosis
disease or disorder
MRI
fingolimod
  • 0 views
  • 17 May, 2021
  • 1 location
featured
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

  • 74 views
  • 25 Mar, 2021
  • 1 location
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab

The open label study to evaluate effectiveness of treatment with ofatumumab in patients transitioning from commonly used oral MS therapies - fingolimod or dimethyl fumarate, due to breakthrough

fingolimod
dimethyl fumarate
ofatumumab
  • 0 views
  • 19 Sep, 2021
  • 119 locations
Long-term Safety Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS

pneumococcal conjugate vaccine
tetanus
ofatumumab
  • 247 views
  • 11 Sep, 2021
  • 262 locations
A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment

The purpose of this study is to compare ofatumumab & chlorambucil (O-Chl) versus ofatumumab & bendamustine (O-B) in patients with Chronic Lymphocytic Leukaemia who are considered not fit

cyclophosphamide
lymphocytosis
chronic lymphocytic leukemia
fludarabine
ofatumumab
  • 436 views
  • 08 Nov, 2020
  • 1 location
A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

To assess whether participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered once every 4 weeks (q4) can mount an adequate immune response to inactivated influenza vaccine as

  • 0 views
  • 12 Sep, 2021
  • 4 locations
9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis

We aim to assess the effect of Ofatumumab on microglial activation using [F-18]PBR06 PET in MS patients in relation to changes in serum markers, MRI abnormalities and clinical impairment

  • 0 views
  • 04 Aug, 2021
  • 1 location
A Single Arm Study Evaluating the Efficacy Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis

A single arm study evaluating the continued efficacy, safety and tolerability of ofatumumab in patients with relapsing multiple sclerosis who are transitioning from aCD20 mAb therapy

ocrelizumab
ofatumumab
  • 0 views
  • 19 Sep, 2021
  • 15 locations
A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

This study will evaluate if participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered once monthly can develop an adequate immune response to the COVID-19 mRNA vaccine compared

  • 0 views
  • 22 Aug, 2021
  • 2 locations
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

ofatumumab, having a more potent anti-CLL activity and complement-dependent cytoxicity than rituximab, could improve disease control and modulate the GVCLL effect more effectively, thus reducing

17p deletion
melphalan
fludarabine
lymphoid leukemia
anti-cd20 monoclonal antibody
  • 12 views
  • 08 Nov, 2020
  • 2 locations